1. All of us, myself included, are trying to interpret the Cumulative CD54 Upregulation vs. Survival data in the absence of enough information and analysis. DNDN has yet to post the data and analysis presented by Dr. Urdal on its website. The P11 trial in ADPC commenced after Provenge's Ph2 data in AIPC was known, but before any Ph 3 data in AIPC was unblinded, and yet, provides for booster dosing. It might be a great idea if some analyst asked Gold during the Q&A after Wednesday's CC to address some of these issues: (a) Expand on Drs. Urdal and Provost's CD54 upregulation presentations (eg. the exact meaning of "Cumulative" CD54 upregulation - Would an additional dose increase the "Cumulative" value as that word is used?); (b) Does DNDN believe that additional doses in AIPC beyond 3 would be beneficial? (c) If not, why not? (d) if so, why didn't DNDN change 9902b's protocol to provide for additional doses?
Good luck to all DNDN longs.
